Heterozygous familial hypercholesterolaemia affects about one in 500 people in the UK. Many patients are asymptomatic at presentation and are discovered because of the chance finding of hypercholesterolaemia. Clinical manifestations include hypercholesterolaemia, atheroma deposits in the coronary arteries leading to ischaemic heart disease at a young age, the presence of xanthomata in tendons and a family history of hypercholesterolaemia or myocardial infarction below the age of 50. 1 Atheromatous deposits may also be found in the root of the aorta and the aortic valve CUSpS2 but is very unusual at other sites. I I describe a patient with heterozygous familial hypercholesterolaemia who exclusively developed aggressive peripheral vascular disease.
CASE HISTORY
cholesterol 11·8 mmol/L, low-density lipoprotein (LDL)-cholesterol 9·5 mrnol/L, high-density lipoprotein (HDL)-cholesterol 1-4mrnol/L, triglyceride 1·2 rnrnol/L, glucose 3·3 rnmol/L, urate 0·27 mmol/L, TSH 1·4 U/L, fibrinogen 3 g/L, A diagnosis of heterozygous familial hypercholesterolaemia was made and she was started on a combination of colestipol and gemfibrozil but she had difficulty in tolerating the oral resin and her serum total cholesterol remained at about 12mrnol/L. She was one of the first patients in the UK to be started on simvastatin given at 40 mg per day in March 1987 which resulted in a fall in her serum total cholesterol to about 9·5 mmol/L ( Fig. 1 ).
Soon afterwards, however, she developed symptoms of peripheral vascular disease. In July 1987 she complained of pain in the right calf on walking 300 yards. Angiography confirmed a stenosis of the right iliac artery which was treated successfully with balloon angioplasty in October 1987. In November 1988 she cholesterol concentration fell to 6·8 mrnol/L following the recommendation that she take I g of vitamin C per day (Fig 1) . She has not reported any adverse effects to her medication-regular ophthalmogical assessment including slit-lamp examination has not demonstrated any pathology and her serum creatine kinase and liver-derived enzymes have remained within the reference ranges.
Heterozygous familial hypercholesterolaemia is classically associated with coronary artery disease yet coronary angiography in November 1987 and January 1991 (performed because she complained of chest tightness on exertion) only demonstrated two areas of aneurysmal dilatation of the right coronary artery, described as 'minor'. No critical narrowings were seen and there was no evidence of progression of disease.
DISCUSSION
The patient has heterozygous familial hypercholesterolaemia yet is atypical in several respects: she has developed profound peripheral vascular disease but not coronary artery disease; 1 she has a past history of hypertension! which one might have expected to be associated with coronary artery disease; she has shown stepwise lowering of serum total cholesterol in response to increasing simvastatin to 80 mg per day;' and her lipid profile was improved by vitamin C supplements. We have not been able to identify any other factor which may have contributed towards a reduction in her serum cholesterol concentration-she did not change Ann Clin Biochem 1997: 34 her diet, she did not lose weight (in fact, her weight has gradually increased since her original attendance to 85 kg at present) and she did not stop any medication known to increase serum cholesterol concentrations. Vitamin C was recommended on an empirical basis" in view of its antioxidant properties and, though we were surprised to find her serum total-and LDLcholesterol were lowered in response, there have been subsequent reports to support this observation. 5 . 6 Chemical interference in the assay for cholesterol by vitamin C 7 was excluded by preincubation of samples with ascorbic oxidase." We hope to investigate how vitamin C may lower serum cholesterol concentration by further studies in the Lipid Clinic.
Could her diagnosis be wrong? Patients with familial combined hyperlipidaemia or type III hyperlipidaemia may develop peripheral and central vascular! disease but we feel that these alternatives have been excluded because both she and other members of her family have serum triglyceride concentrations within the reference range, her serum lipid profile is not characteristic of type III hyperlipidaemia and her apoE phenotype is E2/E3.
Other factors which may contribute towards vascular disease have also been excluded. She keeps to a lipid lowering diet, she does not smoke cigarettes and her hypertension is adequately controlled by tablets. There is no evidence of diabetes mellitus or thyroid disease and her serum urate and fibrinogen are within the reference ranges.
The 5 year period between 1987 and 1992 during which she developed symptoms of peripheral vascular disease was associated with long-standing hyperlipidaemia. She has been asymptomatic since 1992 which coincides with her serum total cholesterol being lowered to 6·8 mmol(L. Serial angiographic studies have since demonstrated that the atheromatous disease of her arteries is now stable and that it is hoped that she will remain free of the effects of her disease.
